SepNet - German Competence Network Sepsis

Motivation:

In critical illness, a significant reduction in mortality was recently achieved by strict glycemic control, however it has to be determined whether this is true and safe for patients with sepsis as well.

As an interdisciplinary network of scientists, the SepNet study group deals with the topics of severe sepsis and septic shock. The aim of the network is to create the prerequisites for better clinical and experimental research into sepsis and thus to develop efficient treatment approaches.

Programme: LIFE Management Cluster

LHA ID: 7RY60E95M5-1

Funding codes:

Novo Nordisk
HemoCue
B. Braun
Federal Ministry of Education and Research (BMBF) FKZ 01 KI 0106

Public web page: https://www.sepsis-stiftung.eu/sepnet/

Human Diseases: Disease by infectious agent

Health Atlas - Local Data Hub/Leipzig PALs: Konrad Reinhart

Project Coordinators: No Project coordinators for this Project

Project start date: 1st Jan 2003

Project Hierarchy

Country: Germany

City: Jena

Web page: https://www.uniklinikum-jena.de

Institute for Medical Informatics, Statistics and Epidemiology (IMISE)

Country: Germany

City: Leipzig

Web page: https://www.imise.uni-leipzig.de/en/

University of Leipzig

Country: Germany

City: Leipzig

Web page: https://www.uni-leipzig.de/en/

Efficacy of Volume Substitution and Insulin Therapy in Severe Sepsis (VISEP Trial)

SepNet - German Competence Network Sepsis

Severe sepsis and septic shock have a high mortality. Research has concentrated on adjunctive sepsis therapies; the role of supportive measures is comparatively unclear. In Europe the use of colloids is widespread, but there is no evidence on the role of either crystalloid or colloid volume therapy in sepsis. Recently, a higher incidence of kidney failure in sepsis was reported after administration of colloids.

Submitter: Christoph Beger

Studies: VISEP

Resources: VISEP metadata, VISEP trial data

Snapshots: No snapshots

Created: 6th May 2019 at 06:37, Last updated: 4th Jun 2020 at 08:34

MAXSEP

SepNet - German Competence Network Sepsis

No description specified

Submitter: René Hänsel

Studies: MAXSEP

Resources: MAXSEP Trial Data, MAXSEP Trial Metadata

Snapshots: No snapshots

Created: 20th May 2019 at 14:24, Last updated: 20th May 2019 at 14:24

SISPCT

SepNet - German Competence Network Sepsis

No description specified

Submitter: René Hänsel

Studies: SISPCT

Resources: SISPCT Trail Data, SISPCT Trail Metadata

Snapshots: No snapshots

Created: 20th May 2019 at 13:47, Last updated: 20th May 2019 at 13:48

HYPRESS

SepNet - German Competence Network Sepsis

No description specified

Submitter: Christoph Beger

Studies: HYPRESS

Resources: HYPRESS Trial Data, HYPRESS Trial Metadata

Snapshots: No snapshots

Created: 20th May 2019 at 13:38, Last updated: 20th May 2019 at 13:38

MAXSEP

SepNet - German Competence Network Sepsis

Baseline Data and Endpoints for MAXSEP

Submitter: René Hänsel

Investigation: MAXSEP

Resources: MAXSEP Trial Data, MAXSEP Trial Metadata

Study type: Not specified

Snapshots: No snapshots

Created: 20th May 2019 at 14:25, Last updated: 20th May 2019 at 14:25

HYPRESS

SepNet - German Competence Network Sepsis

Baseline Data and Endpoints for HYPRESS

Submitter: Christoph Beger

Investigation: HYPRESS

Resources: HYPRESS Trial Data, HYPRESS Trial Metadata

Study type: Not specified

Snapshots: No snapshots

Created: 20th May 2019 at 13:39, Last updated: 20th May 2019 at 13:51

SISPCT

SepNet - German Competence Network Sepsis

Baseline Data and Endpoints for SISPCT

Submitter: René Hänsel

Investigation: SISPCT

Resources: SISPCT Trail Data, SISPCT Trail Metadata

Study type: Not specified

Snapshots: No snapshots

Created: 20th May 2019 at 13:49, Last updated: 20th May 2019 at 13:51

VISEP

SepNet - German Competence Network Sepsis

Baseline Data and Endpoints for VISEP

Submitter: René Hänsel

Investigation: Efficacy of Volume Substitution and Insulin The...

Resources: VISEP metadata, VISEP trial data

Study type: Not specified

Snapshots: No snapshots

Created: 20th May 2019 at 13:11, Last updated: 20th May 2019 at 13:11

SISPCT Trail Metadata

SepNet - German Competence Network Sepsis

No description specified

Submitter: René Hänsel

Resource type: Experimental Assay Type

Technology type: Technology Type

Investigation: SISPCT

Study: SISPCT

Human Diseases: disease by infectious agent

Data files: SISPCT Metadata, SISPCT Metadata-ODM

Snapshots: No snapshots

Created: 20th May 2019 at 13:51, Last updated: 29th Oct 2019 at 10:58

SISPCT Trail Data

SepNet - German Competence Network Sepsis

No description specified

Submitter: René Hänsel

Resource type: Experimental Assay Type

Technology type: Technology Type

Investigation: SISPCT

Study: SISPCT

Human Diseases: disease by infectious agent

Data files: SISPCT, SISPCT-ODM, SISPCT-SPSS

Snapshots: No snapshots

Created: 20th May 2019 at 13:52, Last updated: 29th Oct 2019 at 10:58

MAXSEP Trial Metadata

SepNet - German Competence Network Sepsis

No description specified

Submitter: René Hänsel

Resource type: Experimental Assay Type

Technology type: Technology Type

Investigation: MAXSEP

Study: MAXSEP

Human Diseases: disease by infectious agent

Data files: MAXSEP Metadata, MAXSEP Metadata-ODM

Snapshots: No snapshots

Created: 20th May 2019 at 14:26, Last updated: 29th Oct 2019 at 10:53

MAXSEP Trial Data

SepNet - German Competence Network Sepsis

No description specified

Submitter: René Hänsel

Resource type: Experimental Assay Type

Technology type: Technology Type

Investigation: MAXSEP

Study: MAXSEP

Human Diseases: disease by infectious agent

Data files: MAXSEP, MAXSEP-ODM, MAXSEP-SPSS

Snapshots: No snapshots

Created: 20th May 2019 at 14:27, Last updated: 29th Oct 2019 at 10:53

VISEP trial data

SepNet - German Competence Network Sepsis

The role of intensive insulin therapy in patients with severe sepsis is uncertain. Fluid resuscitation improves survival among patients with septic shock, but evidence is lacking to support the choice of either crystalloids or colloids. We compared intensive insulin therapy with conventional insulin therapy and HES with Ringer’s lactate.

Submitter: René Hänsel

Resource type: Experimental Assay Type

Technology type: Technology Type

Investigation: Efficacy of Volume Substitution and Insulin The...

Study: VISEP

Human Diseases: disease by infectious agent

Data files: VISEP Endpoint, VISEP Endpoint-ODM, VISEP Endpoint-SPSS, VISEP V-PAT, VISEP V-PAT-ODM, VISEP V-PAT-SPSS, VISEP V-VERL-join, VISEP V-VERL-join-ODM, VISEP V-VERL-join-SPSS, VISEP haemo_join, VISEP haemo_join-ODM, VISEP haemo_join-SPSS

Snapshots: No snapshots

Created: 20th May 2019 at 13:16, Last updated: 30th Aug 2019 at 13:30

VISEP metadata

SepNet - German Competence Network Sepsis

Submitter: René Hänsel

Resource type: Experimental Assay Type

Technology type: Technology Type

Investigation: Efficacy of Volume Substitution and Insulin The...

Study: VISEP

Human Diseases: disease by infectious agent

Data files: VISEP Endpoint Metadata, VISEP Endpoint Metadata-ODM, VISEP V-PAT Metadata, VISEP V-PAT Metadata-ODM, VISEP V-VERL-join Metadata, VISEP V-VERL-join Metadata-ODM, VISEP haemo_join Metadata, VISEP haemo_join Metadata-ODM

Snapshots: No snapshots

Created: 20th May 2019 at 13:15, Last updated: 30th Aug 2019 at 13:30

HYPRESS Trial Data

SepNet - German Competence Network Sepsis

Adjunctive hydrocortisone (HC) therapy is suggested by the Surviving Sepsis Campaign in refractory septic shock only. The case for septic patients without shock remains controversial. We investigated the efficacy of HC in patients with severe sepsis without shock

Restricted Trial Data

Submitter: Christoph Beger

Resource type: Result Dataset of Clinical Study

Technology type: Technology Type

Investigation: HYPRESS

Study: HYPRESS

Human Diseases: disease by infectious agent

Data files: HYPRESS Trial Data (Excel), HYPRESS Trial Data (SPSS), Hypress Trial Data (ODM)

Snapshots: No snapshots

Created: 20th May 2019 at 13:42, Last updated: 20th May 2019 at 13:59

HYPRESS Trial Metadata

SepNet - German Competence Network Sepsis

No description specified

Submitter: Christoph Beger

Resource type: Result Dataset of Clinical Study

Technology type: Technology Type

Investigation: HYPRESS

Study: HYPRESS

Human Diseases: disease by infectious agent

Data files: HYPRESS Trial Metadata (Excel), HYPRESS Trial Metadata (ODM)

Snapshots: No snapshots

Created: 20th May 2019 at 13:41, Last updated: 20th May 2019 at 13:59

Effect of a multifaceted educational intervention for anti-infectious measures on sepsis mortality: a cluster randomized trial

SepNet - German Competence Network Sepsis

Abstract (Expand)

PURPOSE Guidelines recommend administering antibiotics within 1 h of sepsis recognition but this recommendation remains untested by randomized trials. This trial was set up to investigate whether …

Authors: Frank Bloos, Hendrik Rüddel, Daniel Thomas-Rüddel, Daniel Schwarzkopf, Christine Pausch, Stephan Harbarth, Torsten Schreiber, Matthias Gründling, John Marshall, Philipp Simon, Mitchell M. Levy, Manfred Weiss, Andreas Weyland, Herwig Gerlach, Tobias Schürholz, Christoph Engel, Claudia Matthäus-Krämer, Christian Scheer, Friedhelm Bach, Reimer Riessen, Bernhard Poidinger, Karin Dey, Norbert Weiler, Andreas Meier-Hellmann, Helene H. Häberle, Gabriele Wöbker, Udo X. Kaisers, Konrad Reinhart

Date Published: 1st Nov 2017

Publication Type: Journal article

Human Diseases: disease by infectious agent

DOI: 10.1007/s00134-017-4782-4

Citation: Intensive Care Med 43(11):1602-1612

Created: 15th Jul 2020 at 14:33, Last updated: 7th Dec 2021 at 17:58

The effect of a novel extracorporeal cytokine hemoadsorption device on IL-6 elimination in septic patients: A randomized controlled trial

SepNet - German Competence Network Sepsis

Abstract (Expand)

OBJECTIVE We report on the effect of hemoadsorption therapy to reduce cytokines in septic patients with respiratory failure. METHODS This was a randomized, controlled, open-label, multicenter trial. …

Authors: Dirk Schädler, Christine Pausch, Daniel Heise, Andreas Meier-Hellmann, Jörg Brederlau, Norbert Weiler, Gernot Marx, Christian Putensen, Claudia Spies, Achim Jörres, Michael Quintel, Christoph Engel, John A. Kellum, Martin K. Kuhlmann

Date Published: 30th Oct 2017

Publication Type: Journal article

Human Diseases: disease by infectious agent

DOI: 10.1371/journal.pone.0187015

Citation: PLoS ONE 12(10):e0187015

Created: 15th Jul 2020 at 14:33, Last updated: 7th Dec 2021 at 17:58

Effect of Hydrocortisone on Development of Shock Among Patients With Severe Sepsis: The HYPRESS Randomized Clinical Trial.

SepNet - German Competence Network Sepsis

(Show All)

Abstract (Expand)

Importance: Adjunctive hydrocortisone therapy is suggested by the Surviving Sepsis Campaign in refractory septic shock only. The efficacy of hydrocortisone in patients with severe sepsis without shock … remains controversial. Objective: To determine whether hydrocortisone therapy in patients with severe sepsis prevents the development of septic shock. Design, Setting, and Participants: Double-blind, randomized clinical trial conducted from January 13, 2009, to August 27, 2013, with a follow-up of 180 days until February 23, 2014. The trial was performed in 34 intermediate or intensive care units of university and community hospitals in Germany, and it included 380 adult patients with severe sepsis who were not in septic shock. Interventions: Patients were randomly allocated 1:1 either to receive a continuous infusion of 200 mg of hydrocortisone for 5 days followed by dose tapering until day 11 (n = 190) or to receive placebo (n = 190). Main Outcomes and Measures: The primary outcome was development of septic shock within 14 days. Secondary outcomes were time until septic shock, mortality in the intensive care unit or hospital, survival up to 180 days, and assessment of secondary infections, weaning failure, muscle weakness, and hyperglycemia (blood glucose level >150 mg/dL [to convert to millimoles per liter, multiply by 0.0555]). Results: The intention-to-treat population consisted of 353 patients (64.9% male; mean [SD] age, 65.0 [14.4] years). Septic shock occurred in 36 of 170 patients (21.2%) in the hydrocortisone group and 39 of 170 patients (22.9%) in the placebo group (difference, -1.8%; 95% CI, -10.7% to 7.2%; P = .70). No significant differences were observed between the hydrocortisone and placebo groups for time until septic shock; mortality in the intensive care unit or in the hospital; or mortality at 28 days (15 of 171 patients [8.8%] vs 14 of 170 patients [8.2%], respectively; difference, 0.5%; 95% CI, -5.6% to 6.7%; P = .86), 90 days (34 of 171 patients [19.9%] vs 28 of 168 patients [16.7%]; difference, 3.2%; 95% CI, -5.1% to 11.4%; P = .44), and 180 days (45 of 168 patients [26.8%] vs 37 of 167 patients [22.2%], respectively; difference, 4.6%; 95% CI, -4.6% to 13.7%; P = .32). In the hydrocortisone vs placebo groups, 21.5% vs 16.9% had secondary infections, 8.6% vs 8.5% had weaning failure, 30.7% vs 23.8% had muscle weakness, and 90.9% vs 81.5% had hyperglycemia. Conclusions and Relevance: Among adults with severe sepsis not in septic shock, use of hydrocortisone compared with placebo did not reduce the risk of septic shock within 14 days. These findings do not support the use of hydrocortisone in these patients. Trial Registration: clinicaltrials.gov Identifier: NCT00670254.

Authors: D. Keh, E. Trips, G. Marx, S. P. Wirtz, E. Abduljawwad, S. Bercker, H. Bogatsch, J. Briegel, C. Engel, H. Gerlach, A. Goldmann, S. O. Kuhn, L. Huter, A. Meier-Hellmann, A. Nierhaus, S. Kluge, J. Lehmke, M. Loeffler, M. Oppert, K. Resener, D. Schadler, T. Schuerholz, P. Simon, N. Weiler, A. Weyland, K. Reinhart, F. M. Brunkhorst

Date Published: 1st Nov 2016

Publication Type: Journal article

Human Diseases: disease by infectious agent

PubMed ID: 27695824

Citation: JAMA. 2016 Nov 1;316(17):1775-1785. doi: 10.1001/jama.2016.14799.

Created: 13th May 2019 at 11:50, Last updated: 7th Dec 2021 at 17:58

Incidence of severe sepsis and septic shock in German intensive care units: the prospective, multicentre INSEP study.

SepNet - German Competence Network Sepsis

Abstract (Expand)

PURPOSE: To estimate the incidence density, point prevalence and outcome of severe sepsis and septic shock in German intensive care units (ICUs). METHODS: In a prospective, multicentre, longitudinal …

Editor:

Date Published: 1st Oct 2016

Publication Type: Journal article

Human Diseases: disease by infectious agent

PubMed ID: 27686355

DOI: 10.1007/s00134-016-4504-3

Citation: Intensive Care Med. 2016 Dec;42(12):1980-1989. doi: 10.1007/s00134-016-4504-3. Epub 2016 Sep 29.

Created: 22nd May 2019 at 12:11, Last updated: 27th Jan 2023 at 08:48

Effect of Sodium Selenite Administration and Procalcitonin-Guided Therapy on Mortality in Patients With Severe Sepsis or Septic Shock: A Randomized Clinical Trial.

SepNet - German Competence Network Sepsis

(Show All)

Abstract (Expand)

IMPORTANCE: High-dose intravenous administration of sodium selenite has been proposed to improve outcome in sepsis by attenuating oxidative stress. Procalcitonin-guided antimicrobial therapy may hasten … the diagnosis of sepsis, but effect on outcome is unclear. OBJECTIVE: To determine whether high-dose intravenous sodium selenite treatment and procalcitonin-guided anti-infectious therapy in patients with severe sepsis affect mortality. DESIGN, SETTING, AND PARTICIPANTS: The Placebo-Controlled Trial of Sodium Selenite and Procalcitonin Guided Antimicrobial Therapy in Severe Sepsis (SISPCT), a multicenter, randomized, clinical, 2 x 2 factorial trial performed in 33 intensive care units in Germany, was conducted from November 6, 2009, to June 6, 2013, including a 90-day follow-up period. INTERVENTIONS: Patients were randomly assigned to receive an initial intravenous loading dose of sodium selenite, 1000 microg, followed by a continuous intravenous infusion of sodium selenite, 1000 microg, daily until discharge from the intensive care unit, but not longer than 21 days, or placebo. Patients also were randomized to receive anti-infectious therapy guided by a procalcitonin algorithm or without procalcitonin guidance. MAIN OUTCOMES AND MEASURES: The primary end point was 28-day mortality. Secondary outcomes included 90-day all-cause mortality, intervention-free days, antimicrobial costs, antimicrobial-free days, and secondary infections. RESULTS: Of 8174 eligible patients, 1089 patients (13.3%) with severe sepsis or septic shock were included in an intention-to-treat analysis comparing sodium selenite (543 patients [49.9%]) with placebo (546 [50.1%]) and procalcitonin guidance (552 [50.7%]) vs no procalcitonin guidance (537 [49.3%]). The 28-day mortality rate was 28.3% (95% CI, 24.5%-32.3%) in the sodium selenite group and 25.5% (95% CI, 21.8%-29.4%) (P = .30) in the placebo group. There was no significant difference in 28-day mortality between patients assigned to procalcitonin guidance (25.6% [95% CI, 22.0%-29.5%]) vs no procalcitonin guidance (28.2% [95% CI, 24.4%-32.2%]) (P = .34). Procalcitonin guidance did not affect frequency of diagnostic or therapeutic procedures but did result in a 4.5% reduction of antimicrobial exposure. CONCLUSIONS AND RELEVANCE: Neither high-dose intravenous administration of sodium selenite nor anti-infectious therapy guided by a procalcitonin algorithm was associated with an improved outcome in patients with severe sepsis. These findings do not support administration of high-dose sodium selenite in these patients; the application of a procalcitonin-guided algorithm needs further evaluation. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00832039.

Authors: F. Bloos, E. Trips, A. Nierhaus, J. Briegel, D. K. Heyland, U. Jaschinski, O. Moerer, A. Weyland, G. Marx, M. Grundling, S. Kluge, I. Kaufmann, K. Ott, M. Quintel, F. Jelschen, P. Meybohm, S. Rademacher, A. Meier-Hellmann, S. Utzolino, U. X. Kaisers, C. Putensen, G. Elke, M. Ragaller, H. Gerlach, K. Ludewig, M. Kiehntopf, H. Bogatsch, C. Engel, F. M. Brunkhorst, M. Loeffler, K. Reinhart

Date Published: 1st Sep 2016

Publication Type: Journal article

Human Diseases: disease by infectious agent

PubMed ID: 27428731

Citation: JAMA Intern Med. 2016 Sep 1;176(9):1266-76. doi: 10.1001/jamainternmed.2016.2514.

Created: 13th May 2019 at 11:44, Last updated: 7th Dec 2021 at 17:58

Biomarker candidates for the detection of an infectious etiology of febrile neutropenia

SepNet - German Competence Network Sepsis

Abstract (Expand)

PURPOSE Infections and subsequent septicemia are major complications in neutropenic patients with hematological malignancies. Here, we identify biomarker candidates for the early detection of an …

Authors: Martin E. Richter, Sophie Neugebauer, Falco Engelmann, Stefan Hagel, Katrin Ludewig, Paul La Rosée, Herbert G. Sayer, Andreas Hochhaus, Marie von Lilienfeld-Toal, Tom Bretschneider, Christine Pausch, Christoph Engel, Frank M. Brunkhorst, Michael Kiehntopf

Date Published: 1st Apr 2016

Publication Type: Journal article

Human Diseases: disease by infectious agent

DOI: 10.1007/s15010-015-0830-6

Citation: Infection 44(2):175-186

Created: 15th Jul 2020 at 14:33, Last updated: 7th Dec 2021 at 17:58

Sepsis survivors monitoring and coordination in outpatient health care (SMOOTH): study protocol for a randomized controlled trial

SepNet - German Competence Network Sepsis

Abstract (Expand)

BACKGROUND Sepsis sequelae include critical illness polyneuropathy, myopathy, wasting, neurocognitive deficits, post-traumatic stress disorder, depression and chronic pain. Little is known howlong-term …

Authors: Konrad Schmidt, Paul Thiel, Friederike Mueller, Katja Schmuecker, Susanne Worrack, Juliane Mehlhorn, Christoph Engel, Katja Brenk-Franz, Stephan Kausche, Ursula Jakobi, Anne Bindara-Klippel, Nico Schneider, Antje Freytag, Dimitry Davydow, Michel Wensing, Frank Martin Brunkhorst, Jochen Gensichen

Date Published: 1st Dec 2014

Publication Type: Journal article

Human Diseases: disease by infectious agent

DOI: 10.1186/1745-6215-15-283

Citation: Trials 15(1),283

Created: 15th Jul 2020 at 14:33, Last updated: 7th Dec 2021 at 17:58

Impact of compliance with infection management guidelines on outcome in patients with severe sepsis: a prospective observational multi-center study.

SepNet - German Competence Network Sepsis

Abstract (Expand)

INTRODUCTION: Current sepsis guidelines recommend antimicrobial treatment (AT) within one hour after onset of sepsis-related organ dysfunction (OD) and surgical source control within 12 hours. The …

Authors: F. Bloos, D. Thomas-Ruddel, H. Ruddel, C. Engel, D. Schwarzkopf, J. C. Marshall, S. Harbarth, P. Simon, R. Riessen, D. Keh, K. Dey, M. Weiss, S. Toussaint, D. Schadler, A. Weyland, M. Ragaller, K. Schwarzkopf, J. Eiche, G. Kuhnle, H. Hoyer, C. Hartog, U. Kaisers, K. Reinhart

Date Published: 3rd Mar 2014

Publication Type: Not specified

Human Diseases: bacterial infectious disease

PubMed ID: 24589043

Citation: Crit Care. 2014 Mar 3;18(2):R42. doi: 10.1186/cc13755.

Created: 13th May 2019 at 12:43, Last updated: 7th Dec 2021 at 17:58

External ventricular drain infections: risk factors and outcome

SepNet - German Competence Network Sepsis

Abstract (Expand)

External ventricular drainage (EVD) is frequently used in neurosurgery to drain cerebrospinal fluid in patients with raised intracranial pressure. We performed a retrospective single center study in …

Authors: S. Hagel, T. Bruns, M. W. Pletz, C. Engel, R. Kalff, C. Ewald

Date Published: 2014

Publication Type: Journal article

Human Diseases: disease by infectious agent

DOI: 10.1155/2014/708531

Citation: Interdisciplinary Perspectives on Infectious Diseases 2014:1-6

Created: 15th Jul 2020 at 14:33, Last updated: 7th Dec 2021 at 17:58

Enteral nutrition is associated with improved outcome in patients with severe sepsis. A secondary analysis of the VISEP trial.

SepNet - German Competence Network Sepsis

Abstract (Expand)

INTRODUCTION: The optimal nutritional strategy remains controversial, particularly in severely septic patients. Our aim was to analyze the effect of three nutritional strategies--enteral (EN), parenteral …

Authors: G. Elke, E. Kuhnt, M. Ragaller, D. Schadler, I. Frerichs, F. M. Brunkhorst, M. Loffler, K. Reinhart, N. Weiler

Date Published: 5th Mar 2013

Publication Type: Not specified

Human Diseases: disease by infectious agent

PubMed ID: 23455443

Citation: Med Klin Intensivmed Notfmed. 2013 Apr;108(3):223-33. doi: 10.1007/s00063-013-0224-4. Epub 2013 Mar 3.

Created: 6th May 2019 at 06:38, Last updated: 7th Dec 2021 at 17:58

View all 21 items

VISEP V-VERL-join

SepNet - German Competence Network Sepsis

No description specified

Creator: Markus Löffler

Submitter: René Hänsel

Data file type: Clinical Data

Investigations: Efficacy of Volume Substitution and Insulin The...

Studies: VISEP

Resources: VISEP trial data

Created: 20th May 2019 at 13:40, Last updated: 25th Feb 2022 at 15:17

VISEP V-PAT-ODM

SepNet - German Competence Network Sepsis

No description specified

Creator: Markus Löffler

Submitter: René Hänsel

Data file type: ODM Data

Investigations: Efficacy of Volume Substitution and Insulin The...

Studies: VISEP

Resources: VISEP trial data

Created: 20th May 2019 at 13:39, Last updated: 28th Jan 2022 at 15:18

VISEP V-PAT-SPSS

SepNet - German Competence Network Sepsis

No description specified

Creator: Markus Löffler

Submitter: René Hänsel

Data file type: Clinical Data

Investigations: Efficacy of Volume Substitution and Insulin The...

Studies: VISEP

Resources: VISEP trial data

Created: 20th May 2019 at 13:38, Last updated: 28th Jan 2022 at 15:18

MAXSEP-ODM

SepNet - German Competence Network Sepsis

No description specified

Creator: Marita Ziepert

Submitter: René Hänsel

Data file type: ODM Data

Investigations: MAXSEP

Studies: MAXSEP

Resources: MAXSEP Trial Data

Created: 20th May 2019 at 14:31, Last updated: 28th Jan 2022 at 15:18

MAXSEP

SepNet - German Competence Network Sepsis

No description specified

Creator: Marita Ziepert

Submitter: René Hänsel

Data file type: Clinical Data

Investigations: MAXSEP

Studies: MAXSEP

Resources: MAXSEP Trial Data

Created: 20th May 2019 at 14:30, Last updated: 28th Jan 2022 at 15:18

MAXSEP-SPSS

SepNet - German Competence Network Sepsis

No description specified

Creator: Marita Ziepert

Submitter: René Hänsel

Data file type: Clinical Data

Investigations: MAXSEP

Studies: MAXSEP

Resources: MAXSEP Trial Data

Created: 20th May 2019 at 14:31, Last updated: 28th Jan 2022 at 15:18

VISEP V-VERL-join-SPSS

SepNet - German Competence Network Sepsis

No description specified

Creator: Markus Löffler

Submitter: René Hänsel

Data file type: Clinical Data

Investigations: Efficacy of Volume Substitution and Insulin The...

Studies: VISEP

Resources: VISEP trial data

Created: 20th May 2019 at 13:40, Last updated: 28th Jan 2022 at 15:18

VISEP haemo_join-SPSS

SepNet - German Competence Network Sepsis

No description specified

Creator: Markus Löffler

Submitter: René Hänsel

Data file type: Clinical Data

Investigations: Efficacy of Volume Substitution and Insulin The...

Studies: VISEP

Resources: VISEP trial data

Created: 20th May 2019 at 13:33, Last updated: 28th Jan 2022 at 15:18

SISPCT-ODM

SepNet - German Competence Network Sepsis

No description specified

Creator: Christoph Engel

Submitter: René Hänsel

Data file type: ODM Data

Investigations: SISPCT

Studies: SISPCT

Resources: SISPCT Trail Data

Created: 20th May 2019 at 13:57, Last updated: 28th Jan 2022 at 15:18

VISEP haemo_join-ODM

SepNet - German Competence Network Sepsis

No description specified

Creator: Markus Löffler

Submitter: René Hänsel

Data file type: ODM Data

Investigations: Efficacy of Volume Substitution and Insulin The...

Studies: VISEP

Resources: VISEP trial data

Created: 20th May 2019 at 13:35, Last updated: 28th Jan 2022 at 15:18

View all 35 items

Holger Bogatsch

Projects: SepNet - German Competence Network Sepsis

Institutions: Institute for Medical Informatics, Statistics and Epidemiology (IMISE)

LHA Data Portal Bot

Projects: LIFE - Leipzig Research Center for Civilization Diseases, LHA - Leipzig Health Atlas, GLA - German Lymphoma Alliance, SepNet - German Competence Network Sepsis

Institutions: University of Leipzig

René Hänsel

Projects: LHA - Leipzig Health Atlas, LIFE Adult, LIFE - Leipzig Research Center for Civilization Diseases, LIFE HNC - Head and Neck Cancer Group, LIFE Heart, MMML - Molecular mechanisms in malignant lymphoma, GLA - German Lymphoma Alliance, MMML Demonstrators - Molecular Mechanisms in Malignant Lymphomas - Demonstrators of Personalized Medicine, HaematoOpt - Individualized model-based managing of the next-cycle thrombopenia of CHOEP/CHOP treated patients based on platelets dynamics during the previous cycles, e:Med, GC-HBOC - German Consortium for Hereditary Breast and Ovarian Cancer, GC-HNPCC - German Consortium for Hereditary Non-Polyposis Colorectal Cancer, MMML-MYC-SYS, NLP4CR - Natural Language Processing for Clinical Research, Genetical Statistics and Systems Biology, SepNet - German Competence Network Sepsis, LIFE Child, HNPCC-Sys - Genomic and transcriptomic heterogeneity of colorectal tumours arising in Lynch syndrome, GGN - German Glioma Network, CAPSys - Footprints of Sepsis Framed Within Community Acquired Pneumonia in the Blood Transcriptome, CapSys - Systems Medicine of Community Acquired Pneumonia, ProstataCA, HaematoSys - Systems biology of haematopoiesis and haematopoietic neoplasia, SMITH - Smart Medical Information Technology for Healthcare, Task Force COVID-19 Leipzig, NFDI4Health, POLAR - Polypharmacy, Drug Interactions, Risks, Management of health information systems, LivSys Transfer - Transfer of the LivSys in vitro system for hepatotoxicity into application, Project Test Demonstrator, Fundus photography as tool for analysis of eyes of subjects with diabetes, Clinical Trials Leipzig, NFDI4Health - TA3 Services, STOP-NUC, SCALE-TORT, EarlyAMDRate

Institutions: Institute for Medical Informatics, Statistics and Epidemiology (IMISE)

https://orcid.org/0000-0001-8344-0658

Roles: Technician

Expertise: Data Management, Data analysis, Python, Html

Markus Löffler

Projects: LHA - Leipzig Health Atlas, LIFE Adult, LIFE - Leipzig Research Center for Civilization Diseases, LIFE HNC - Head and Neck Cancer Group, MMML - Molecular mechanisms in malignant lymphoma, GLA - German Lymphoma Alliance, MMML Demonstrators - Molecular Mechanisms in Malignant Lymphomas - Demonstrators of Personalized Medicine, MMML-MYC-SYS, Genetical Statistics and Systems Biology, SepNet - German Competence Network Sepsis, HaematoSys - Systems biology of haematopoiesis and haematopoietic neoplasia, e:Med, SMITH - Smart Medical Information Technology for Healthcare, Task Force COVID-19 Leipzig, NFDI4Health, POLAR - Polypharmacy, Drug Interactions, Risks

Institutions: Institute for Medical Informatics, Statistics and Epidemiology (IMISE), University of Leipzig

Prof. Dr. Markus Löffler Universität Leipzig Institut für Medizinische Informatik, Statistik und Epidemiologie Härtelstraße 16-18 04107 Leipzig

Konrad Reinhart

Projects: SepNet - German Competence Network Sepsis

Institutions: Department of Anesthesiology and Intensive Care Medicine Friedrich Schiller University of Jena

LIFE Management Cluster

No description specified

Projects: LIFE Heart, LIFE - Leipzig Research Center for Civilization Diseases, LIFE HNC - Head and Neck Cancer Group, SepNet - German Competence Network Sepsis, GC-HNPCC - German Consortium for Hereditary Non-Polyposis Colorectal Cancer, LIFE Child, GC-HBOC - German Consortium for Hereditary Breast and Ovarian Cancer, LIFE Adult

Web page: https://www.uniklinikum-leipzig.de/einrichtungen/life

disease by infectious agent

SepNet - German Competence Network Sepsis, LIFE - Leipzig Research Center for Civilization Diseases, CAPSys - Footprints of Sepsis Framed Within Community Acquired Pneumonia in the Blood Transcriptome

Taxonomy URI: http://purl.obolibrary.org/obo/DOID_0050117

Synonyms: infectious disease

Definitions: A disease that is the consequence of the presence of pathogenic microbial agents, including pathogenic viruses, pathogenic bacteria, fungi, protozoa, multicellular parasites, and aberrant proteins known as prions.

SepNet - German Competence Network Sepsis

Navigate

Health Atlas - Local Data Hub/Leipzig

Registered Repository

SepNet - German Competence Network Sepsis

Related items

Navigate

Health Atlas - Local Data Hub/Leipzig

Registered Repository